NASDAQ
YDES
Last Price
US $1.90
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
YD Bio Limited Ordinary Shares cash flow to debt ratio of -97.53K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
YD Bio Limited Ordinary Shares's free cash flow has decreased 69.27% from $-4.75M last year to $-8.04M, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
YD Bio Limited Ordinary Shares's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
YD Bio Limited Ordinary Shares's debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials
Financial risk - Net debt/EBITDA.
YD Bio Limited Ordinary Shares has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
YD Bio Limited Ordinary Shares earns at least as much interest as it pays. Interest obligations are fully covered.
Financial stability - Profit margin growth.
YD Bio Limited Ordinary Shares's profit margin has increased (-100.00%) in the last year from -276.58% to 0.00%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
YD Bio Limited Ordinary Shares's short-term assets of $9.67M exceed its short-term liabilities of $1.64M
Decreasing performance - ROA.
YD Bio Limited Ordinary Shares's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Increasing performance - Absolute return on equity.
YD Bio Limited Ordinary Shares's return on equity of 80.82%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
YD Bio Limited Ordinary Shares's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Increasing performance - Earnings stability.
YD Bio Limited Ordinary Shares had positive net income in 3.00 out of 5 years, indicating stable and consistent earnings
Decreasing performance - Free cash flow.
YD Bio Limited Ordinary Shares has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
YD Bio Limited Ordinary Shares has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
YD Bio Limited Ordinary Shares's yearly earnings has decreased 488.80% since last year from $-1.41M to $-8.31M, signaling decreasing performance
Increasing performance - Healthy revenue growth.
YD Bio Limited Ordinary Shares's yearly revenue has increased 16.94% since last year from $510.36K to $596.82K, signaling increasing performance
Decreasing performance - ROIC.
ROIC -9.26% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
YD Bio Limited Ordinary Shares has insufficient revenue history to calculate 3-year revenue CAGR.
Increasing performance - Revenue consistency.
YD Bio Limited Ordinary Shares had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Increasing performance - ROE consistency.
YD Bio Limited Ordinary Shares had positive ROE in 3.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
YD Bio Limited Ordinary Shares has insufficient data to evaluate this check.
Overvalued - Earnings yield.
YD Bio Limited Ordinary Shares has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
YD Bio Limited Ordinary Shares is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
YD Bio Limited Ordinary Shares has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
YD Bio Limited Ordinary Shares has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
YD Bio Limited Ordinary Shares has negative shareholder equity; price-to-book is not meaningful and the check fails
Overvalued - P/S ratio.
YD Bio Limited Ordinary Shares has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
80.82%
Return on equity
ROIC: -9.26%
Valuation History
-1.5X
Price to Earnings
EV/EBITDA: -31.1X
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Fair Value
Market $1.90
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.